Evidence map›Paper›PMID 23782813›Full record

ArticleBiology of mood & anxiety disorders2013

Mapping anhedonia onto reinforcement learning: a behavioural meta-analysis.

Quentin Jm Huys, Diego A Pizzagalli, Ryan Bogdan, Peter Dayan

Registry-linked trialAbstract read
In one paragraph

Article in Biology of mood & anxiety disorders, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07369115 (Intra-Cellular Therapies, Inc. / "A Randomized, Double-blind, Placebo-controlled, Single Site Study to Evaluate the Efficacy of Lumateperone for the Treatment of Major Depressive Disorder), which is not on this map. Cited by 219 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
219citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07369115 phase4not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Intra-Cellular Therapies, Inc. / "A Randomized, Double-blind, Placebo-controlled, Single Site Study to Evaluate the Efficacy of Lumateperone for the Treatment of Major Depressive Disorder (MDD) and Early Life Trauma in Adult Patients Aged 21 to 70 Years

TypeinterventionalSponsorUniversity of Texas at AustinRan2026 to 2030Enrolled50ConditionsMajor Depressive Diorder, Early Life TraumaArmsLumateperone 42 mg, Placebo
3 · Its place in the literature

Who cites it

219 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Computationally Informed Insights Into Anhedonia and Treatment by Kappa Opioid Receptor Antagonism.Biological psychiatry. Cognitive neuroscience and neuroimaging · 2025
    Trial
  6. Depression Severity Moderates Reward Learning Among Smokers With Current or Past Major Depressive Disorder in a Smoking Cessation Randomized Clinical Trial.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2024
    Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Review
  20. Article

159 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Quentin Jm HuysGatsby Computational Neuroscience Unit, UCL, London, UK. qhuys@cantab.net.
Diego A Pizzagalli
Ryan Bogdan
Peter Dayan

Funding

Neuroimaging Studies of Reward Processing in DepressionR01MH068376 · NIMH · MCLEAN HOSPITAL · PI PIZZAGALLI, DIEGO A · 2004 to 2014
$4.5M
Multi level Analysis of Positive Valence Systems Across Mood DisordersR01MH101521 · NIMH · MCLEAN HOSPITAL · PI PIZZAGALLI, DIEGO A · 2013 to 2016
$2.1M
Translational Measures of anhedonia in humans and ratsR21MH078979 · NIMH · MCLEAN HOSPITAL · PI PIZZAGALLI, DIEGO A · 2008 to 2009
$430k
The effects of SAMe on reward circuitry in depressionR21AT002974 · NCCIH · HARVARD UNIVERSITY · PI PIZZAGALLI, DIEGO A · 2006 to 2007
$409k
NCCIH NIH HHS R21 AT002974NIMH NIH HHS R01 MH068376NIMH NIH HHS R01 MH101521NIMH NIH HHS R21 MH078979
6 · The paper itself

Abstract

backgroundDepression is characterised partly by blunted reactions to reward. However, tasks probing this deficiency have not distinguished insensitivity to reward from insensitivity to the prediction errors for reward that determine learning and are putatively reported by the phasic activity of dopamine neurons. We attempted to disentangle these factors with respect to anhedonia in the context of stress, Major Depressive Disorder (MDD), Bipolar Disorder (BPD) and a dopaminergic challenge.

methodsSix behavioural datasets involving 392 experimental sessions were subjected to a model-based, Bayesian meta-analysis. Participants across all six studies performed a probabilistic reward task that used an asymmetric reinforcement schedule to assess reward learning. Healthy controls were tested under baseline conditions, stress or after receiving the dopamine D2 agonist pramipexole. In addition, participants with current or past MDD or BPD were evaluated. Reinforcement learning models isolated the contributions of variation in reward sensitivity and learning rate.

resultsMDD and anhedonia reduced reward sensitivity more than they affected the learning rate, while a low dose of the dopamine D2 agonist pramipexole showed the opposite pattern. Stress led to a pattern consistent with a mixed effect on reward sensitivity and learning rate.

conclusionReward-related learning reflected at least two partially separable contributions. The first related to phasic prediction error signalling, and was preferentially modulated by a low dose of the dopamine agonist pramipexole. The second related directly to reward sensitivity, and was preferentially reduced in MDD and anhedonia. Stress altered both components. Collectively, these findings highlight the contribution of model-based reinforcement learning meta-analysis for dissecting anhedonic behavior.

Identifiers

PMID23782813
PMCPMC3701611

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.